Department of Pathology, University Medical Center Utrecht Cancer Center, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Breast Cancer Res Treat. 2012 Dec;136(3):705-15. doi: 10.1007/s10549-012-2301-4. Epub 2012 Oct 27.
Promoter hypermethylation of several tumour suppressor genes often occurs during breast carcinogenesis, but little is known about epigenetic silencing in the possible precursor columnar cell lesion (CCL). Promoter hypermethylation of 50 different tumour suppressor genes was assessed in normal breast tissue (N = 10), CCL (N = 15), ductal carcinoma in situ (DCIS) grade I originating in CCL (N = 5) and paired CCL (N = 15) with DCIS (N = 7) and/or invasive carcinoma (N = 14) by Methylation-specific multiplex ligation-dependent probe amplification. Increasing mean cumulative methylation levels were found from normal breast tissue to CCL to DCIS and invasive carcinoma (P < 0.001) with similar methylation levels in DCIS and invasive carcinoma. Methylation levels and frequencies (in the overall analysis and analysis of only the synchronous lesions) were the highest for RASSF1, CCND2, ID4, SCGB3A1 and CDH13. The methylation levels of ID4, CCND2, and CDH13 increased significantly from normal breast tissue to CCL and to DCIS/invasive carcinoma. RASSF1, SCGB3A1 and SFRP5 had significant higher methylation levels in CCL compared to normal breast tissue, but showed no significant differences between CCL, DCIS and invasive carcinoma. Also, no difference was found between CCLs with and without atypia, or CCLs with or without synchronous cancer. In conclusion, promoter hypermethylation for several established tumour suppressor genes is already present in CCLs, underlining that promoter hypermethylation is an early event in breast carcinogenesis. Atypia in CCL or the presence of synchronous more advanced lesions does not seem to be accompanied by higher methylation levels.
在乳腺癌发生过程中,多个肿瘤抑制基因的启动子经常发生高甲基化,但对于可能的前体柱状细胞病变(CCL)中的表观遗传沉默知之甚少。通过甲基化特异性多重连接依赖性探针扩增,评估了正常乳腺组织(N=10)、CCL(N=15)、起源于 CCL 的导管原位癌(DCIS)I 级(N=5)和配对的 CCL(N=15)伴 DCIS(N=7)和/或浸润性癌(N=14)中 50 个不同肿瘤抑制基因的启动子高甲基化。从正常乳腺组织到 CCL 再到 DCIS 和浸润性癌,发现平均累积甲基化水平逐渐升高(P<0.001),DCIS 和浸润性癌的甲基化水平相似。RASSF1、CCND2、ID4、SCGB3A1 和 CDH13 的甲基化水平和频率(在总体分析和仅同步病变的分析中)最高。ID4、CCND2 和 CDH13 的甲基化水平从正常乳腺组织到 CCL 再到 DCIS/浸润性癌显著增加。与正常乳腺组织相比,CCL 中的 RASSF1、SCGB3A1 和 SFRP5 具有更高的甲基化水平,但 CCL、DCIS 和浸润性癌之间没有显著差异。此外,有或没有非典型增生的 CCL 之间,或有或没有同步癌症的 CCL 之间,也没有发现差异。总之,几个已确立的肿瘤抑制基因的启动子高甲基化已经存在于 CCL 中,这强调了启动子高甲基化是乳腺癌发生的早期事件。CCL 中的非典型增生或存在同步更高级别的病变似乎不会伴有更高的甲基化水平。